Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2007

3M Granted License to Inhibitex’ Protein Platform

  • Inhibitex entered into a license and commercialization agreement with 3M for the development of various diagnostic products using Inhibitex's MSCRAMM® protein platform. Under the terms of the agreement, Inhibitex granted 3M an exclusive global license to use Clumping Factor A (ClfA), an MSCRAMM protein, in the development of diagnostic products to detect Staphylococcus aureus and other bacterial and fungal pathogens.

    Inhibitex will receive over $4 million over the next five years, including license fees, future milestone payments, financial support for further research and development activities, and royalty payments on product sales. 3M also received a license to use additional MSCRAMM protein targets for the development of other diagnostic products.
    MSCRAMM proteins are a family of proteins located on the surface of pathogenic organisms.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »